Investor News / RNS

Physiomics presents at the BioTrinity 2019 meeting in London Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it presented today at the BioTrinity 2019 annual conference in London.  The presentation is available on the “resources” section of our website here https://www.physiomics.co.uk/wp-content/uploads/2019/04/Physiomics-Presentation-Biotrinity-2019.pdf. The Company also took the opportunity to meet...

The Company considers that the award of options linked to company performance are critical to the incentivisation of its senior employees and to ensure that there is alignment between management and shareholders.  To this end, the Company today confirms that it has agreed to issue share options to its directors, as detailed in this announcement.  Each option forming part of this award is exercisable at...

  AIM Rule 26 Website Change  Physiomics updates its branding, website and URL to improve customer experience Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce it has undertaken an exercise to “modernise and simplify” its online image in advance of its attendance at the American Association for Cancer Research Annual Meeting...

Physiomics to present on personalised medicine and Virtual Tumour™ developments at AACR 2019 meeting Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Association of Cancer Research (“AACR”) Annual Meeting 2019, taking place in Atlanta, Georgia, 29th March to 3rd April.  The company...

Oxford, UK, 21 February 2019: The Board of Physiomics Plc, a provider of technology- based solutions to predict the effects of cancer treatment regimens for the biopharma industry (AIM: PYC), today announces its financial results for the six months ended 31 December 2018. Click here to read in full. ...

Physiomics plc (AIM: PYC), is pleased to announce that it will be attending the Biotech Showcase partnering conference in San Francisco from 7-9 January 2019 during the JP Morgan Healthcare Conference week. During this week, many of the world’s most successful biotech and pharmaceutical companies are present in San Francisco to meet with prospective clients and partners. Over three thousand attendees are expected to participate...

Physiomics plc (AIM: PYC), is pleased to announce that it has entered into a strategic collaboration with the Medicines Discovery Catapult. Physiomics will be part of the “Virtual R&D” network of advisors and available to provide advice to the many small biotechnology companies supported by Medicines Discovery Catapult. Click here to read in full.  ...

Physiomics plc (Oxford, UK) is pleased to announce that, following a successful collaboration this year and pursuant to the Master Services Agreement signed with Merck, a leading science and technology company, in November 2017, it has agreed with its client a program of work for the next calendar year. Click here to read in full....

The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to shareholders were passed. Please click here to read in full....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report for the financial year ended 30th June 2018 and a Circular in relation to its forthcoming Annual General Meeting Please click here to read in full....